|
Jun 6
|
Valneva reports data from Phase II chikungunya vaccine trial in children
|
|
Jun 5
|
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
|
|
Jun 5
|
[Valneva SE] Declaration of shares and voting rights - May 2025
|
|
Jun 4
|
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
|
|
May 26
|
Valneva to Participate at U.S. and European Investor Conferences in June
|
|
May 8
|
Valneva SE (INRLF) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...
|
|
May 7
|
VALNEVA Declaration of shares and voting rights: April 30, 2025
|
|
May 7
|
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
|
|
May 7
|
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
|
|
Apr 28
|
France halts Valneva’s chikungunya vaccine use in seniors
|
|
Mar 10
|
High Growth Tech Stocks In Europe For March 2025
|
|
Feb 18
|
Valneva hits 2024 sales target but plans lower cash burn in 2025
|
|
Feb 18
|
Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook
|
|
Feb 17
|
Bavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teens
|